A study to compare the benefits between itraconazole and terbinafine with itraconazole in skin fungal infections
Not Applicable
- Conditions
- Health Condition 1: B359- Dermatophytosis, unspecified
- Registration Number
- CTRI/2022/12/047904
- Lead Sponsor
- nil
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Subjects aged between 18-65 years of age with clinical diagnosis of dermatophytosis(tinea corporis,tinea faciei,tinea cruris) including all new cases & recurrent cases of dermatophytosis
Exclusion Criteria
Pregnant & lactating women
Subjects with history of preexisting liver & renal disease
Subjects with history of HIV or under antiretroviral therapy
Subjects with history of hypersensitivity to the drugs under study
Subjects under immunosuppressive therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Itching <br/ ><br>Erythema <br/ ><br>Scaling <br/ ><br>Timepoint: <br/ ><br>At baseline,3,6 and 9 weeks
- Secondary Outcome Measures
Name Time Method Any side effects like GI disturbances, headache, rashes, allergic symptoms <br/ ><br> <br/ ><br>Timepoint: 0,3,6 and 9 weeks